Latest Breaking News On - Yat sen university cancer center - Page 1 : comparemela.com

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 HUTCHMED Limited today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be.

Hangzhou
Zhejiang
China
Qing-zhai
Shanghai
Feng-wang
Hunan
United-states
Renji
Henan
Yang-wang
Shanxi

HUTCHMED Highlights Presentations at the 2024 ASCO Annual

HUTCHMED Highlights Presentations at the 2024 ASCO Annual
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

China
Guangzhou
Guangdong
Hangzhou
Zhejiang
Sheng-li
Anhui
Yang-wang
Shanxi
Chicago
Illinois
United-states

HUTCHMED Presentations at 2024 ASCO Annual Meeting | Company Announcement

Investegate announcements from HUTCHMED Presentations at 2024 ASCO Annual Meeting

Qing-zhai
Zhejiang
China
Zhengzhou
Henan
Yang-wang
Shanxi
Hong-kong
Tongji
Sichuan
Chicago
Illinois

Sun Yat-sen University Cancer Center Reports Findings in Prescription Opioids (Trends in pain undertreatment among lung cancer patients at the EOL: Analysis of urban city medical insurance data in China): Opioids - Prescription Opioids - Insurance News

Sun Yat-sen University Cancer Center Reports Findings in Prescription Opioids (Trends in pain undertreatment among lung cancer patients at the EOL: Analysis of urban city medical insurance data in China): Opioids - Prescription Opioids - Insurance News
insurancenewsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insurancenewsnet.com Daily Mail and Mail on Sunday newspapers.

China
United-states
Junyi
Shaanxi
Li-zhang
Zhejiang
Guangzhou
Guangdong
Mengting-shi
Yuanyuan-zhao
Yunpeng-yang
Jiani-zheng

BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting

CAMBRIDGE, Mass. & BEIJING (BUSINESS WIRE) May 19, 2021 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results and updates from its broad portfolio will be presented at the 2021 Annual Meeting of the American Society of Cancer Oncology (ASCO) being held June 4 â 8, 2021. âWe are pleased to share updates from our growing clinical portfolio across solid tumors and hematologic malignancies at this yearâs ASCO, including multiple novel combinations of tislelizumab with our investigational Fc-competent anti-TIGIT-antibody ociperlimab and other therapeutic agents, and the ongoing evaluation of our next-generation BTK inhibitor zanubrutinib,â commented Lai Wang, Ph.D., Global Head of R&D at BeiGene. âWe believe that these presentations underscore the breadth and diversity, as well as the remarkable progress and momentum, in BeiGeneâ�

Australia
Japan
Tongji
Sichuan
China
Shanghai
United-states
Beijing
Canada
Lin-shen
Guangdong
Seoul